Cencora (COR) Stock Declines – What's Behind the Drop?

This afternoon we watched Cencora drop -4.2% to a price of $227.28 per share. The Large-Cap Pharmaceutical company is now trading -12.17% below its average target price of $258.78. Analysts have set target prices ranging from $229.0 to $280.0 per share for Cencora, and have given the stock an average rating of buy.

Cencora has an average level of shares sold short, at 6.5% of its total share float. The stock's short ratio (also called days to cover) is 6.42. The company's insiders own 13.48% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.

Institutional investors own 88.5% of Cencora's shares, which indicates they have a high level of confidence in the company.

Institutions Invested in Cencora

Date Reported Holder Percentage Shares Value
2024-03-31 Walgreens Boots Alliance, Inc. 13% 26,277,561 $5,972,364,032
2024-03-31 Vanguard Group Inc 10% 20,348,522 $4,624,812,055
2024-03-31 Blackrock Inc. 10% 19,197,966 $4,363,313,689
2024-03-31 Price (T.Rowe) Associates Inc 5% 8,986,455 $2,042,441,481
2024-03-31 State Street Corporation 4% 7,921,778 $1,800,461,694
2024-03-31 FMR, LLC 3% 5,455,887 $1,240,013,990
2024-03-31 Wellington Management Group, LLP 3% 5,015,230 $1,139,861,468
2024-03-31 JP Morgan Chase & Company 2% 4,937,221 $1,122,131,582
2023-12-31 Boston Partners 2% 4,032,600 $916,529,323
2024-03-31 Geode Capital Management, LLC 2% 3,918,579 $890,614,630
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.